Australian Group on Antimicrobial Resistance (AGAR) Australian Staphylococcus aureus Surveillance Outcome Program (ASSOP) Bloodstream Infection Annual Report 2022
DOI:
https://doi.org/10.33321/cdi.2023.47.67Keywords:
Australian Group on Antimicrobial Resistance (AGAR), antimicrobial resistance surveillance, Staphylococcus aureus, methicillin-susceptible Staphylococcus aureus (MSSA), methicillin-resistant Staphylococcus aureus (MRSA), bacteraemiaAbstract
From 1 January to 31 December 2022, fifty-five institutions across Australia participated in the Australian Staphylococcus aureus Surveillance Outcome Program (ASSOP). The aim of ASSOP 2022 was to determine the proportion of Staphylococcus aureus bacteraemia (SAB) isolates in Australia that were antimicrobial resistant, with particular emphasis on susceptibility to methicillin and on characterisation of the molecular epidemiology of the methicillin-resistant isolates. A total of 3,214 SAB episodes were reported, of which 77.5% were community-onset. Overall, 15.0% of S. aureus were methicillin resistant. The 30-day all-cause mortality associated with methicillin-resistant SAB was 21.4%, which was significantly different to the 16.8% all-cause mortality associated with methicillin-susceptible SAB (p = 0.02). With the exception of the β-lactams and erythromycin, antimicrobial resistance in methicillin-susceptible S. aureus was rare. However, in addition to the β-lactams, approximately 31% of methicillin-resistant S. aureus (MRSA) were resistant to ciprofloxacin; 30% to erythromycin; 13% to tetracycline; 11% to gentamicin; and 2% to co-trimoxazole. One MRSA isolate, with a daptomycin MIC of 1.5 mg/L, harboured the A302V mprF and A23V cls2 mutations. When applying the European Committee on Antimicrobial Susceptibility Testing (EUCAST) breakpoints, teicoplanin resistance was detected in one MRSA isolate. Resistance to vancomycin or linezolid was not detected. Resistance to non-β-lactam antimicrobials was largely attributable to the healthcare-associated MRSA (HA-MRSA) clone ST22-IV [2B] (EMRSA-15), and to the community-associated MRSA (CA-MRSA) clone ST45-V [5C2&5] which has acquired resistance to multiple antimicrobials including ciprofloxacin, clindamycin, erythromycin, gentamicin, and tetracycline. The ST22-IV [2B] (EMRSA-15) clone is the predominant HA-MRSA clone in Australia. Nonetheless, 86% of methicillin-resistant SAB episodes were due to CA-MRSA clones. Although polyclonal, approximately 72% of CA-MRSA clones were characterised as ST93-IV [2B] (Queensland clone); ST5-IV [2B]; ST45-V [5C2&5]; ST1-IV [2B]; ST30-IV [2B]; ST97-IV [2B]; ST953-IV [2B]; and ST8-IV [2B]. As CA-MRSA is well established in the Australian community, it is important to monitor antimicrobial resistance patterns in community- and healthcare-associated SAB as this information will guide therapeutic practices in treating S. aureus bacteraemia.
Downloads
References
Laupland KB. Incidence of bloodstream infection: a review of population-based studies. Clin Microbiol Infect. 2013;19(6):492–500. doi: https://doi.org/10.1111/1469-0691.12144.
Johnson AP, Pearson A, Duckworth G. Surveillance and epidemiology of MRSA bacteraemia in the UK. J Antimicrob Chemother. 2005;56(3):455–62. doi: https://doi.org/10.1093/jac/dki266.
Boucher HW, Talbot GH, Bradley JS, Edwards JE, Gilbert D, Rice LB et al. Bad bugs, no drugs: no ESKAPE! An update from the Infectious Diseases Society of America. Clin Infect Dis. 2009;48(1):1–12. doi: https://doi.org/10.1086/595011.
Thwaites GE, Edgeworth JD, Gkrania-Klotsas E, Kirby A, Tilley R, Török ME et al. Clinical management of Staphylococcus aureus bacteraemia. Lancet Infect Dis. 2011;11(3):208–22. doi: https://doi.org/10.1016/S1473-3099(10)70285-1.
van Hal SJ, Jensen SO, Vaska VL, Espedido BA, Paterson DL, Gosbell IB. Predictors of mortality in Staphylococcus aureus bacteremia. Clin Microbiol Rev. 2012;25(2):362–86. doi: https://doi.org/10.1128/CMR.05022-11.
Collignon P, Nimmo GR, Gottlieb T, Gosbell IB for the Australian Group on Antimicrobial Resistance. Staphylococcus aureus bacteremia, Australia. Emerg Infect Dis. 2005;11(4):554–61. doi: https://doi.org/10.3201/eid1104.040772.
Frederiksen MS, Espersen F, Frimodt-Møller N, Jensen AG, Larsen AR, Pallesen LV et al. Changing epidemiology of pediatric Staphylococcus aureus bacteremia in Denmark from 1971 through 2000. Pediatr Infect Dis J. 2007;26:398–405. doi: https://doi.org/10.1097/01.inf.0000261112.53035.4c.
Benfield T, Espersen F, Frimodt-Møller N, Jensen AG, Larsen AR, Pallesen LV et al. Increasing incidence but decreasing in-hospital mortality of adult Staphylococcus aureus bacteraemia between 1981 and 2000. Clin Microbiol Infect. 2007;13(3):257–63. doi: https://doi.org/10.1111/j.1469-0691.2006.01589.x.
Turnidge JD, Kotsanas D, Munckhof W, Roberts S, Bennett CM, Nimmo GR et al. Staphylococcus aureus bacteraemia: a major cause of mortality in Australia and New Zealand. Med J Aust. 2009;191(7):368–73. doi: https://doi.org/10.5694/j.1326-5377.2009.tb02841.x.
Nimmo GR, Bell JM, Collignon PJ for the Australian Group on Antimicrobial Resistance. Fifteen years of surveillance by the Australian Group for Antimicrobial Resistance (AGAR). Commun Dis Intell Q Rep. 2003;27(Suppl):S47–54.
Coombs GW, Nimmo GR, Daly DA, Le TT, Pearson JC, Tan HL et al. Australian Staphylococcus aureus Sepsis Outcome Programme annual report, 2013. Commun Dis Intell Q Rep. 2014;38(4):E309–19.
Clinical and Laboratory Standards Institute (CLSI). Performance standards for antimicrobial susceptibility testing. 33rd ed. CLSI supplement M100. Wayne, PA: CLSI; 3 March 2023.
The European Committee on Antimicrobial Susceptibility Testing (EUCAST). Breakpoint tables for interpretation of MICs and zone diameters. Version 13.1. Basel: EUCAST; 29 June 2023. Available from: https://www.eucast.org/fileadmin/src/media/PDFs/EUCAST_files/Breakpoint_tables/v_13.1_Breakpoint_Tables.pdf.
Seemann T, Goncalves da Silva A, Bulach DM, Schultz MB, Kwong JC, Howden BP. Nullarbor. San Francisco; Github. [Accessed on 3 Jun 2016.] Available from: https://github.com/tseemann/nullarbor.
Hasman H, Saputra D, Sicheritz-Ponten T, Lund O, Aaby Svendsen CA, Frimodt-Møller N et al. Rapid whole-genome sequencing for detection and characterization of microorganisms directly from clinical samples. J Clin Microbiol. 2014;52(1):139–46. doi: https://doi.org/10.1128/JCM.02452-13.
Larsen MV, Cosentino S, Lukjancenko O, Saputra D, Rasmussen S, Hasman H et al. Benchmarking of methods for genomic taxonomy. J Clin Microbiol. 2014;52(5):1529–39. doi: https://doi.org/10.1128/JCM.02981-13.
Clausen PTLC, Aarestrup FM, Lund O. Rapid and precise alignment of raw reads against redundant databases with KMA. BMC Bioinformatics. 2018;19(1):307. doi: https://doi.org/10.1186/s12859-018-2336-6.
International Working Group on The Classification of Staphylococcal Cassette Chromosome Elements (IWG-SCC). Classification of staphylococcal cassette chromosome mec (SCCmec): guidelines for reporting novel SCCmec elements. Antimicrob Agents Chemother. 2009;53(12):4961–7. doi: https://doi.org/10.1128/AAC.00579-09.
European Centre for Disease Prevention and Control (ECDC). European Antimicrobial Resistance Surveillance Network (EARS-Net). [Webpage.] Solna: ECDC; 2023. Available from: https://www.ecdc.europa.eu/en/about-us/networks/disease-networks-and-laboratory-networks/ears-net-data.
ECDC. Surveillance Atlas of Infectious Diseases. [Webpage.] Solna: ECDC; 28 April 2023. Available from: https://www.ecdc.europa.eu/en/surveillance-atlas-infectious-diseases.
ECDC/World Health Organization (WHO) Regional Office for Europe. Antimicrobial resistance surveillance in Europe 2023 – 2021 data. Solna: ECDC; 14 April 2023. Available from: https://www.ecdc.europa.eu/en/publications-data/antimicrobial-resistance-surveillance-europe-2023-2021-data.
Johnson AP, Davies J, Guy R, Abernethy J, Sheridan E, Pearson A et al. Mandatory surveillance of methicillin-resistant Staphylococcus aureus (MRSA) bacteraemia in England: the first 10 years. J Antimicrob Chemother. 2012;67(4):802–9. doi: https://doi.org/10.1093/jac/dkr561.
de Kraker ME, Davey PG, Grundmann H, BURDEN study group. Mortality and hospital stay associated with resistant Staphylococcus aureus and Escherichia coli bacteremia: estimating the burden of antibiotic resistance in Europe. PLoS Med. 2011;8(10):e1001104. doi: https://doi.org/10.1371/journal.pmed.1001104.
Vos MC, Behrendt MD, Melles DC, Mollema FP, de Groot W, Parlevliet G et al. 5 years of experience implementing a methicillin-resistant Staphylococcus aureus search and destroy policy at the largest university medical center in the Netherlands. Infect Control Hosp Epidemiol. 2009;30(10):977–84. doi: https://doi.org/10.1086/605921.
Grayson ML, Jarvie LJ, Martin R, Johnson PD, Jodoin ME, McMullan C et al. Significant reductions in methicillin-resistant Staphylococcus aureus bacteraemia and clinical isolates associated with a multisite, hand hygiene culture-change program and subsequent successful statewide roll-out. Med J Aust. 2008;188(11):633–40. doi: https://doi.org/10.5694/j.1326-5377.2008.tb01820.x.
Kim YC, Kim MH, Song JE, Ahn JY, Oh DH, Kweon OM et al. Trend of methicillin-resistant Staphylococcus aureus (MRSA) bacteremia in an institution with a high rate of MRSA after the reinforcement of antibiotic stewardship and hand hygiene. Am J Infect Control. 2013;41(5):e39–43. doi: https://doi.org/10.1016/j.ajic.2012.12.018.
Lawes T, Edwards B, López-Lozano JM, Gould I. Trends in Staphylococcus aureus bacteraemia and impacts of infection control practices including universal MRSA admission screening in a hospital in Scotland, 2006–2010: retrospective cohort study and time-series intervention analysis. BMJ Open. 2012;2(3). pii: e000797. doi: https://doi.org/10.1136/bmjopen-2011-000797.
Coombs GW, Daley DA, Thin Lee Y, Pearson JC, Robinson JO, Nimmo GR et al. Australian Group on Antimicrobial Resistance Australian Staphylococcus aureus Sepsis Outcome Programme annual report, 2014. Commun Dis Intell Q Rep. 2016;40(2):E244–54.
Coombs GW, Daley DA, Lee YT, Pang S, Bell JM, Turnidge JD et al. Australian Group on Antimicrobial Resistance (AGAR) Australian Staphylococcus aureus Sepsis Outcome Programme (ASSOP) Annual Report 2015. Commun Dis Intell (2018). 2018;42. pii: S2209-6051(18)00016-7.
Coombs GW, Daley DA, Lee YT, Pang S for the Australian Group on Antimicrobial Resistance. Australian Group on Antimicrobial Resistance (AGAR) Australian Staphylococcus aureus Sepsis Outcome Programme (ASSOP) annual report 2016. Commun Dis Intell (2018). 2018;42. pii: S2209-6051(18)00021-0.
Coombs GW, Daley DA, Lee YT, Pang S. Australian Group on Antimicrobial Resistance (AGAR) Australian Staphylococcus aureus Sepsis Outcome Programme (ASSOP) annual report 2017. Commun Dis Intell (2018). 2019;43. doi: https://doi.org/10.33321/cdi.2019.43.43.
Coombs GW, Daley DA, Mowlaboccus S, Lee YT, Pang S, Australian Group on Antimicrobial Resistance. Australian Group on Antimicrobial Resistance (AGAR) Australian Staphylococcus aureus Sepsis Outcome Programme (ASSOP) annual report 2018. Commun Dis Intell (2018). 2020;44. doi: https://doi.org/10.33321/cdi.2020.44.18.
Coombs GW, Daley DA, Mowlaboccus S, Pang S, Australian Group on Antimicrobial Resistance. Australian Group on Antimicrobial Resistance (AGAR) Australian Staphylococcus aureus Sepsis Outcome Programme (ASSOP) Annual Report 2019. Commun Dis Intell (2018). 2020;44. doi: 10.33321/cdi.2020.44.71.
Coombs GW, Daley DA, Yee NWT, Shoby P, Mowlaboccus S, Australian Group on Antimicrobial Resistance. Australian Group on Antimicrobial Resistance (AGAR) Australian Staphylococcus aureus Sepsis Outcome Programme (ASSOP) Annual Report 2020. Commun Dis Intell (2018). 2022;46. doi: https://doi.org/cdi.2022.46.18.
Coombs GW, Daley DA, Shoby P, Mowlaboccus S, Australian Group on Antimicrobial Resistance. Australian Group on Antimicrobial Resistance (AGAR) Australian Staphylococcus aureus Surveillance Outcome Program (ASSOP) Bloodstream Annual Report 2021. Commun Dis Intell (2018). 2022; 46. doi: https://doi.org/cdi.2022.46.76.
O’Brien FG, Pearman JW, Gracey M, Riley TV, Grubb WB. Community strain of methicillin-resistant Staphylococcus aureus involved in a hospital outbreak. J Clin Microbiol. 1999;37(9):2858–62. doi: https://doi.org/10.1128/JCM.37.9.2858-2862.
Schlebusch S, Price GR, Hinds S, Nourse C, Schooneveldt JM, Tilse MH et al. First outbreak of PVL-positive nonmultiresistant MRSA in a neonatal ICU in Australia: comparison of MALDI-TOF and SNP-plus-binary gene typing. Eur J Clin Microbiol Infect Dis. 2010;29(10):1311–4. doi: https://doi.org/10.1007/s10096-010-0995-y.
Published
How to Cite
License
Copyright (c) 2023 Communicable Diseases Intelligence
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
